Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:BNTC NASDAQ:CRDL NASDAQ:DMAC NASDAQ:LXEO On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$14.92+5.1%$13.30$9.10▼$17.15$372.76M0.4163,723 shs67,114 shsCRDLCardiol Therapeutics$1.04-4.6%$1.11$0.77▼$2.24$93.68M1.02748,075 shs602,895 shsDMACDiaMedica Therapeutics$6.64-5.4%$6.24$3.19▼$7.49$362.86M1.4319,935 shs381,533 shsLXEOLexeo Therapeutics$8.24+0.5%$5.50$1.45▼$11.72$442.81M1.661.29 million shs1.47 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma+5.07%+7.80%+11.84%+16.74%+61.12%CRDLCardiol Therapeutics-4.59%-2.80%-4.59%-19.38%-43.17%DMACDiaMedica Therapeutics-5.41%-6.08%-6.87%+82.92%+47.56%LXEOLexeo Therapeutics+0.49%+24.47%+58.46%+84.34%-3.06%Compare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeBNTCBenitec Biopharma$14.92+5.1%$13.30$9.10▼$17.15$372.76M0.4163,723 shs67,114 shsCRDLCardiol Therapeutics$1.04-4.6%$1.11$0.77▼$2.24$93.68M1.02748,075 shs602,895 shsDMACDiaMedica Therapeutics$6.64-5.4%$6.24$3.19▼$7.49$362.86M1.4319,935 shs381,533 shsLXEOLexeo Therapeutics$8.24+0.5%$5.50$1.45▼$11.72$442.81M1.661.29 million shs1.47 million shsAnalysts Agree—These Gold Picks Outshine the RestUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceBNTCBenitec Biopharma+5.07%+7.80%+11.84%+16.74%+61.12%CRDLCardiol Therapeutics-4.59%-2.80%-4.59%-19.38%-43.17%DMACDiaMedica Therapeutics-5.41%-6.08%-6.87%+82.92%+47.56%LXEOLexeo Therapeutics+0.49%+24.47%+58.46%+84.34%-3.06%Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceBNTCBenitec Biopharma 2.70Moderate Buy$24.8066.22% UpsideCRDLCardiol Therapeutics 3.00Buy$8.00669.23% UpsideDMACDiaMedica Therapeutics 2.50Moderate Buy$12.3385.74% UpsideLXEOLexeo Therapeutics 2.71Moderate Buy$17.00106.31% UpsideCurrent Analyst Ratings BreakdownLatest CRDL, DMAC, BNTC, and LXEO Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails10/8/2025BNTCBenitec BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025CRDLCardiol TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/8/2025LXEOLexeo TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)10/7/2025LXEOLexeo TherapeuticsChardan CapitalSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$15.00 ➝ $17.0010/7/2025LXEOLexeo TherapeuticsHC WainwrightSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetBuy$9.00 ➝ $15.0010/7/2025LXEOLexeo TherapeuticsLeerink PartnersSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingBoost Price TargetOutperform$9.00 ➝ $20.0010/6/2025BNTCBenitec BiopharmaZacks ResearchSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingDowngradeHold ➝ Strong Sell9/27/2025BNTCBenitec BiopharmaWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025CRDLCardiol TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)9/27/2025DMACDiaMedica TherapeuticsWeiss RatingsSubscribe to MarketBeat All Access for the firm's recommendation accuracy ratingReiterated RatingSell (D-)(Data available from 10/11/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookBNTCBenitec Biopharma$80K4,895.63N/AN/A$3.71 per share4.02CRDLCardiol TherapeuticsN/AN/AN/AN/A$0.22 per shareN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/A$0.95 per shareN/ALXEOLexeo Therapeutics$650K684.55N/AN/A$3.53 per share2.33Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateBNTCBenitec Biopharma-$37.92M-$1.47N/AN/AN/AN/A-46.19%-43.88%11/13/2025 (Estimated)CRDLCardiol Therapeutics-$26.77M-$0.34N/AN/AN/AN/A-232.26%-158.19%11/13/2025 (Estimated)DMACDiaMedica Therapeutics-$24.44M-$0.69N/AN/AN/AN/A-78.99%-69.94%11/12/2025 (Estimated)LXEOLexeo Therapeutics-$98.33M-$3.26N/AN/AN/AN/A-94.65%-73.36%11/12/2025 (Estimated)Latest CRDL, DMAC, BNTC, and LXEO EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails9/25/2025Q4 2025BNTCBenitec Biopharma-$0.24-$0.42-$0.18-$0.42N/AN/A8/14/2025Q2 2025CRDLCardiol Therapeutics-$0.11-$0.07+$0.04-$0.07N/AN/A8/14/2025Q2 2025LXEOLexeo Therapeutics-$0.64-$0.60+$0.04-$0.60N/AN/A8/12/2025Q2 2025DMACDiaMedica Therapeutics-$0.18-$0.18N/A-$0.18N/AN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthBNTCBenitec BiopharmaN/AN/AN/AN/AN/ACRDLCardiol TherapeuticsN/AN/AN/AN/AN/ADMACDiaMedica TherapeuticsN/AN/AN/AN/AN/ALXEOLexeo TherapeuticsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioBNTCBenitec Biopharma0.0154.6754.67CRDLCardiol Therapeutics0.012.462.46DMACDiaMedica TherapeuticsN/A7.557.55LXEOLexeo TherapeuticsN/A4.434.43Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipBNTCBenitec Biopharma52.19%CRDLCardiol Therapeutics12.49%DMACDiaMedica Therapeutics10.12%LXEOLexeo Therapeutics60.67%Insider OwnershipCompanyInsider OwnershipBNTCBenitec Biopharma1.30%CRDLCardiol Therapeutics5.25%DMACDiaMedica Therapeutics7.30%LXEOLexeo Therapeutics5.30%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableBNTCBenitec Biopharma2026.25 million25.91 millionNo DataCRDLCardiol Therapeutics2085.94 million81.43 millionNot OptionableDMACDiaMedica Therapeutics2051.69 million47.92 millionOptionableLXEOLexeo Therapeutics5854.00 million51.14 millionNot OptionableCRDL, DMAC, BNTC, and LXEO HeadlinesRecent News About These CompaniesQ3 EPS Estimate for Lexeo Therapeutics Raised by Analyst3 hours ago | marketbeat.comLexeo Therapeutics (NASDAQ:LXEO) Earns "Sell (D-)" Rating from Weiss RatingsOctober 10 at 6:57 AM | marketbeat.comHC Wainwright & Co. Maintains Lexeo Therapeutics (LXEO) Buy RecommendationOctober 8 at 12:39 AM | msn.comLeerink Partners Maintains Lexeo Therapeutics (LXEO) Outperform RecommendationOctober 8 at 2:58 AM | msn.comLexeo Therapeutics Stock Rallies On Discussions With FDA To Expedite Friedreich’s Ataxia Drug Approval ProcessOctober 7, 2025 | msn.comLexeo Therapeutics stock soars after FDA accelerated approval progressOctober 7, 2025 | investing.comLexeo climbs after regulatory update on Friedreich ataxia drugOctober 7, 2025 | msn.comLexeo Therapeutics Shares Surge 25% on FDA Accelerated Approval Pathway ProgressOctober 7, 2025 | msn.comLexeo: Maintaining Buy Rating Based On FDA Accelerated Approval FeedbackOctober 7, 2025 | seekingalpha.comLexeo Therapeutics, Inc. - Special CallOctober 7, 2025 | seekingalpha.comLexeo Therapeutics (NASDAQ:LXEO) Price Target Raised to $20.00October 7, 2025 | marketbeat.comLexeo Therapeutics Advances FDA Discussions for LX2006October 7, 2025 | tipranks.comLexeo Therapeutics Announces Progress in FDA Discussions for Accelerated Approval Pathway and Positive Interim Clinical Data for LX2006 in Friedreich Ataxia CardiomyopathyOctober 7, 2025 | globenewswire.comPalumbo Wealth Management LLC Invests $226,000 in Lexeo Therapeutics, Inc. $LXEOSeptember 26, 2025 | marketbeat.comLexeo Therapeutics, Inc. (NASDAQ:LXEO) Receives Average Rating of "Buy" from BrokeragesSeptember 19, 2025 | marketbeat.comIs Lexeo Therapeutics (NASDAQ:LXEO) In A Good Position To Invest In Growth?August 29, 2025 | finance.yahoo.comInsider Selling: Lexeo Therapeutics (NASDAQ:LXEO) CEO Sells 2,735 Shares of StockAugust 21, 2025 | insidertrades.comLexeo Therapeutics’ Friedreich Ataxia Gene Therapy Receives FDA Breakthrough Therapy DesignationAugust 20, 2025 | msn.comLexeo Therapeutics price target lowered to $15 from $20 at ChardanAugust 16, 2025 | msn.comLexeo Therapeutics reports Q2 EPS (60c) vs (64c) last yearAugust 14, 2025 | msn.comLexeo Therapeutics Appoints New Chief Financial OfficerAugust 14, 2025 | tipranks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCRDL, DMAC, BNTC, and LXEO Company DescriptionsBenitec Biopharma NASDAQ:BNTC$14.92 +0.72 (+5.07%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$14.51 -0.41 (-2.77%) As of 10/10/2025 05:44 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Benitec Biopharma Inc., a clinical-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference-based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy. The company was incorporated in 1995 and is headquartered in Hayward, California.Cardiol Therapeutics NASDAQ:CRDL$1.04 -0.05 (-4.59%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$1.04 +0.00 (+0.48%) As of 10/10/2025 07:01 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Cardiol Therapeutics Inc., a clinical-stage life sciences company, focuses on the research and development of anti-fibrotic and anti-inflammatory therapies for the treatment of heart diseases. Its lead product CardiolRx, which is in Phase II multi-national, randomized, double-blind, and placebo-controlled study to evaluate the efficacy and safety of CardiolRx in acute myocarditis, as well as for the treatment of recurrent pericarditis. The company is also developing CRD-38 injection for subcutaneous administration that is in preclinical development for the treatment of heart failure. It has a license agreement with Meros. The company was incorporated in 2017 and is headquartered in Oakville, Canada.DiaMedica Therapeutics NASDAQ:DMAC$6.64 -0.38 (-5.41%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$6.54 -0.11 (-1.58%) As of 10/10/2025 07:34 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.DiaMedica Therapeutics Inc., a clinical stage biopharmaceutical company, focuses on improving the lives of people suffering from serious diseases with a focus on acute ischemic stroke. Its lead candidate is DM199, a pharmaceutically active recombinant form of the human tissue kallikrein-1 protein, which is in Phase II/III trials for the treatment of acute ischemic stroke, as well as that is in Phase 2 to treat cardio-renal disease. The company also develops DM300, which is in preclinical stage for the treatment of severe inflammatory diseases. In addition, it develops treatment for neurological disease. The company was formerly known as DiaMedica Inc. and changed its name to DiaMedica Therapeutics Inc. in December 2016. DiaMedica Therapeutics Inc. was incorporated in 2000 and is headquartered in Minneapolis, Minnesota.Lexeo Therapeutics NASDAQ:LXEO$8.24 +0.04 (+0.49%) Closing price 10/10/2025 04:00 PM EasternExtended Trading$8.26 +0.03 (+0.30%) As of 10/10/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Lexeo Therapeutics, Inc. operates as a clinical stage genetic medicine company that focuses on hereditary and acquired diseases. The company develops LX2006, which is an AAVrh10-based gene therapy candidate for the treatment of Friedreich's ataxia (FA) cardiomyopathy; LX2020, an AAVrh10-based gene therapy candidate for the treatment of plakophilin-2 arrhythmogenic cardiomyopathy; LX2021, a gene therapy candidate for the treatment of DSP cardiomyopathy associated with it; and LX2022, a gene therapy candidate for the treatment of hypertrophic cardiomyopathy, or HCM caused by TNNI3 gene. It also develops LX1001, an AAVrh10-based gene therapy candidate for the treatment of APOE4 homozygous; LX1020, a gene therapy candidate for the treatment of APOE4 homozygous; LX1021 for the treatment of APOE4 homozygotes; and LX1004 for the treatment of CLN2 Batten disease. The company was incorporated in 2017 and is based in New York, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30DroneEcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerFlying CarGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMade In AmericaMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUraniumUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Broadcom Gets Second $420 Target as CPO Win Boosts Outlook Why Amazon’s Prime Day May Be the Catalyst for a Year-End Rally PepsiCo’s Deep Discount Will Soon Evaporate: Buy It While You Can Bargain Alert: DraftKings Is the Most Oversold It’s Ever Been Constellation Brands: Buffett’s $2.2B Bet May Have Hit Bottom How Gamers Are Powering Microsoft’s Next Wave of Growth AI Meets Nuclear: Palantir’s Role in Energy Expansion Buy the Dip? Zillow’s Profit Comeback Meets Market Pressure Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
